newsfilter
← Latest News
GlobeNewswire·

Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn's Disease

FORT COLLINS, Colo., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced submission to